High Growth Tech Stocks in Australia for October 2024

The Australian market has remained flat over the past week but has experienced a 15% increase over the past year, with earnings forecasted to grow by 12% annually. In this context, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable market conditions.

Top 10 High Growth Tech Companies In Australia

Name	Revenue Growth	Earnings Growth	Growth Rating
Clinuvel Pharmaceuticals	22.32%	27.42%	★★★★★★
Adherium	86.80%	73.66%	★★★★★★
ImExHS	20.47%	111.20%	★★★★★★
Telix Pharmaceuticals	20.10%	38.31%	★★★★★★
AVA Risk Group	32.56%	118.83%	★★★★★★
Pointerra	56.62%	126.45%	★★★★★★
Careteq	37.17%	126.21%	★★★★★☆
Wrkr	36.31%	100.29%	★★★★★★
Adveritas	57.98%	144.21%	★★★★★★
SiteMinder	19.65%	60.64%	★★★★★☆

Click here to see the full list of 64 stocks from our ASX High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Life360 (ASX:360)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Life360, Inc. operates a technology platform focused on locating people, pets, and things across various regions including North America and internationally, with a market cap of approximately A$4.64 billion.

Operations: The company generates revenue primarily from its software and programming segment, amounting to $328.68 million. It operates across multiple regions including North America, Europe, the Middle East, and Africa.

Life360's strategic enhancements and partnerships are setting a robust pace in the tech sector, with a notable revenue increase to $84.86 million this quarter from $70.79 million last year, reflecting a growth of 15.7%. This surge is complemented by its innovative product launches like the new Tile Bluetooth trackers, which not only expand its product range but also integrate seamlessly with Life360's app to enhance user safety and connectivity. Moreover, updates in partnerships with Arity and Placer.ai promise to bolster advertising revenues and data sales, aligning with an upgraded annual revenue forecast of $370 million to $378 million. These moves showcase Life360’s agility in adapting to tech trends while pushing for substantial annual earnings growth projected at 68.5%.

• Delve into the full analysis health report here for a deeper understanding of Life360.

• Gain insights into Life360's past trends and performance with our Past report.

Pro Medicus (ASX:PME)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system software to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe with a market cap of A$19.56 billion.

Operations: The company generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$161.50 million. Its operations span Australia, North America, and Europe, focusing on imaging software and radiology information systems for hospitals and healthcare groups.

Pro Medicus, a standout in the Australian tech landscape, has demonstrated robust financial health with a significant year-over-year revenue jump from AUD 127.33 million to AUD 166.33 million and an impressive net income increase from AUD 60.65 million to AUD 82.79 million. This growth trajectory is underpinned by a strategic focus on research and development (R&D), crucial for maintaining technological leadership and innovation in healthcare imaging software solutions. The company's commitment to reinvesting in its core capabilities is evident from its R&D spending trends, aligning with an anticipated revenue growth rate of 17% per year, which surpasses the broader Australian market's average of 5.5%. Furthermore, Pro Medicus announced a substantial dividend increase to 40 cents fully franked this fiscal year, reflecting confidence in sustained profitability and cash flow positivity—a testament to its operational efficiency and forward-looking management practices.

• Dive into the specifics of Pro Medicus here with our thorough health report.

• Examine Pro Medicus' past performance report to understand how it has performed in the past.

REA Group (ASX:REA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: REA Group Limited operates as an online property advertising business across Australia, India, the United States, Malaysia, Singapore, Thailand, Vietnam, and internationally with a market capitalization of A$28.68 billion.

Operations: The company generates revenue primarily from its online property advertising segment in Australia, contributing A$1.25 billion, alongside financial services and operations in India. The Australian property and online advertising segment is a significant driver of its business model.

REA Group, navigating through a challenging landscape, has managed to project earnings growth of 16.8% per year, outpacing the Australian market's average of 12.2%. This growth is supported by a robust R&D commitment, which not only fuels innovation but also aligns with an upward trend in revenue growth projected at 6.5% annually—faster than the market's 5.5%. Despite a recent downturn in net income from AUD 356.1 million to AUD 302.8 million year-over-year, REA has increased its dividend payout by 23%, signaling confidence in future cash flows and financial health.

• Unlock comprehensive insights into our analysis of REA Group stock in this health report.

• Explore historical data to track REA Group's performance over time in our Past section.

Key Takeaways

• Investigate our full lineup of 64 ASX High Growth Tech and AI Stocks right here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com